Do you want to read an article? Please log in or register.
Prognostic Value of STAS, Lymph Node Metastasis, and VPI in NSCLC ≤ 4 cm Treated with Lobectomy
Lung CancerPleural Diseases
Related content
RECOMMENDED
Lung Cancer
Prognostic Value of (18)F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Kocaaslan E, Güren AK, Akagündüz F, Demirel A, Tunç MA, Paçacı B, Ağyol Y, Erel P, Çelebi A, Işık S, Çoban E, Demircan NC, Özgüven S, Balaban Genç ZC, Majidova N, Sever N, Sarı M, Köstek O, Bayoğlu IV
doi: 10.3390/jcm15020798
Lung Cancer
Prognostic Analysis of Different Histological Types of 2-3 cm pN0M0 Carcinoma Based on Surgical Procedure: A SEER Database Study
Clin Lung Cancer
Wang Z, Xu Y, Chen C, Ye M, Xu S, Chen S
doi: 10.1016/j.cllc.2026.02.006
Lung Cancer
Comparative Outcomes of Segmentectomy Versus Lobectomy for Solid Dominant Lung Cancer with a Tumor Diameter of 2-3 cm
J Clin Med
Mitsuboshi S, Omata M, Shidei H, Ogihara A, Isaka T, Kanzaki M
doi: 10.3390/jcm15062244
RECOMMENDED
Lung Cancer
Optimizing Lymph Node Staging in Non-Small Cell Lung Cancer Surgery: Evidence, Guidelines, and Quality Improvement Strategies
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Magouliotis DE, Androutsopoulou V, Cioffi U, Minervini F, Sicouri N, Xanthopoulos A, Scarci M
doi: 10.3390/jcm15020831
Lung Cancer
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes
Cancer Treat Rev
Marinelli D, Citarella F, Torchia A, Pannu S, Aijaz A, Sisca L, Russano M, Fujiwara Y, Takada K, Nassar AH, Banna GL, Ricciuti B, Brunetti L, Santo V, Passaro A, Saw SPL, Li MSC, Addeo A, Ferrara R, Di Maio M, Mountzios G, Santini D, Maugeri-Saccà M, Vincenzi B, Acker F, Reckamp KL, Cappuzzo F, Naqash AR, Cortellini A
doi: 10.1016/j.ctrv.2026.103159
Lung Cancer
Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer
J Clin Med
Nuransoy Cengiz A, Bozkurt O, Cengiz M, Ozkan M, Inanc M, Kefeli U, Cabuk D, Erman M, Kilickap S, Koseci T, Bayir D, Guven DC, Urun M, Cosar R, Sakalar T, Majidova N, Mutlu Ozkan E, Akosman C, Ersoy M, Sahin E, Can Sanci P, Yildiz C, Kolemen E, Agdas G, Kocaaslan E, Turkoğlu E, Yildirim S, Mermit Ercek B, Karakayali A, Arvas H, Kidi MM, Biter S, Yesil Cinkir H, Karahan L, Apaydin Rollas AE
doi: 10.3390/jcm15020642
Lung Cancer
Artificial Intelligence and Endobronchial Ultrasound for Lymph-Node Detection and Characterization: A Pioneer Multicenter Transatlantic Study
J Clin Med
Mascarenhas M, Nuevo GD, Lopes S, Sancho JP, Garcia-Gallo CL, Oliveira LB, Chinzon M, Assis LM, Ejima G, Maluf-Filho F, Carvalho MF, Dias TPL, Chirichela IA, Ribeiro T, Mendes F, Pérez A, Agudo Castillo B, Costa APD, González-Haba M, Fonseca J, Macedo G, Moura EGH, Ferreira JP, Brito JMLT, Machuca TN, Scordamaglio PR, Oliveira FND, Leite-Moreira AF
doi: 10.3390/jcm15145356
Lung CancerPleural Diseases
Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%)
J Clin Med
Djordjevic F, Ljujic K, Stanic N, Nikolic N, Markovic I, Spasic J
doi: 10.3390/jcm14176200
RECOMMENDED
Lung Cancer
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Adv Ther
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M
doi: 10.1007/s12325-025-03465-4